Sage Therapeutics

Major pharmaceutical and biotech companies including Pfizer, Johnson & Johnson, Fate Therapeutics, and Generation Bio are implementing workforce reductions as part of industry-wide financial restructuring efforts.

Biogen reported Leqembi generated $160 million in global sales for Q2 2024, representing a 58% increase, with U.S. sales rising 20% to $63 million despite ongoing market adoption challenges.

Supernus Pharmaceuticals announced a definitive agreement to acquire Sage Therapeutics for $8.50 per share upfront plus contingent payments up to $3.50 per share, totaling up to $795 million.

Supernus Pharmaceuticals agreed to acquire Sage Therapeutics for up to $795 million, offering $8.50 per share in cash plus contingent value rights worth $3.50 per share based on sales milestones.

Ellipsis Health secured $45 million in Series A funding led by Salesforce, Khosla Ventures, and CVS Health Ventures to advance AI-powered care management solutions.

A comprehensive pipeline report reveals over 75 companies are developing innovative treatments for major depressive disorder, with several promising candidates advancing through Phase III trials.

SageMedic Corp. is presenting its SAGE Oncotest™, an ex-vivo 3D microtumor assay that evaluates live tumor tissue responses to FDA-approved therapies, at the AACR Annual Meeting in Chicago.

• Sage Therapeutics and Biogen's SAGE-324 shows no significant benefit in Phase II KINETIC 2 study for essential tremor treatment. • Jazz Pharmaceuticals experiences setback as suvecaltamide fails to meet primary and key secondary endpoints in Phase IIb essential tremor trial. • Recent trial failures highlight ongoing challenges in developing effective treatments for essential tremor, a condition affecting millions worldwide.

• Biogen approaches Q4 earnings with Wall Street projecting $3.35 adjusted EPS and $2.40 billion in sales, while facing challenges in Leqembi adoption and market penetration. • FDA approved Leqembi's new maintenance dosing schedule for Alzheimer's disease, allowing four-week intervals after initial bi-weekly treatment phase. • European regulatory developments and higher dose nusinersen applications for SMA highlight Biogen's expanding therapeutic portfolio despite market headwinds.

Biogen has entered into a strategic funding agreement with Royalty Pharma, securing $250 million over six quarters to advance litifilimab, a promising lupus treatment, into Phase III development.